Podcast Summary: Dr. Chapa’s Clinical Pearls
Episode: TOLAC: IOL or Wait? (March 2025 Data)
Date Aired: February 22, 2025
Host: Dr. Chapa (with co-host Sam and others)
Episode Overview
This episode takes a deep dive into the soon-to-be-published (March 2025) research on whether to induce labor or wait for spontaneous labor in women choosing TOLAC (Trial of Labor After Cesarean). Dr. Chapa reviews the latest population-level data, placing it in direct contrast to the existing ACOG guidelines—highlighting the evolving, sometimes contradictory nature of clinical recommendations. The tone is enthusiastic, clinically relevant, and practical, designed to empower listeners with nuanced, up-to-date knowledge for patient counseling.
Key Discussion Points and Insights
1. Background and Setup
- ACOG Guidance Reference:
- The episode centers on the comparison between current ACOG Practice Bulletin #205 (Feb 2019, reaffirmed Aug 2024) and a new, large study coming in the American Journal of ObGyn in March 2025.
- ACOG’s 2019 stance: Induction can be offered for TOLAC candidates, but spontaneous labor is associated with higher VBAC success and a lower risk of uterine rupture.
- Clinical Context:
- Focuses on low-risk women with a single prior cesarean, no medical comorbidities, and attempting "primary" TOLAC.
Notable Quote:
- “That’s what to do with a patient who wants a TOLAC at term. Should we do an induction of labor or allow expectant management for spontaneous labor?... this new population-level data ... is totally in contrast to ACOG’s guidance from 2019.” — [00:57]
2. The Historical Standard: ACOG Bulletin 205 (2019, reaffirmed 2024)
- 2019 Guidance Quotes:
- Induction is allowed for TOLAC (excluding prostaglandins and certain conditions).
- “Induced labor is associated with a lower likelihood of achieving VBAC.” — [06:26]
- Slightly increased risk of uterine rupture with induction, yet overall risk remains low and induction is permitted.
- Nuances:
- VBAC success varies with Bishop score, prior vaginal birth, indication for cesarean, etc.
Notable Quote:
- “When compared with spontaneous labor, induced labor is associated with a lower likelihood of achieving VBAC.” — [06:26, quoting ACOG]
3. The New Study: March 2025 Data Preview
- Design & Inclusion:
- US birth certificate data, 2016–2021.
- Included: singleton, vertex pregnancies, one prior cesarean, no prior vaginal delivery, no comorbidities, delivered from ≥39⁰–≤42⁶ weeks.
- Excluded: prior vaginal delivery, deliveries outside 39–42⁶ weeks, medical comorbidity.
- Primary Outcome:
- Vaginal delivery rates (VBAC success).
- Secondary Outcomes:
- Maternal and neonatal morbidity (e.g., uterine rupture, operative vaginal delivery, hysterectomy, ICU admission, transfusion).
4. Study Results & Direct Comparison [Starts ~14:58]
- Study Population:
- 198,797 qualifying women (2016–2021).
- 87% managed expectantly (waited for spontaneous labor); 13% had induction at 39⁰–39⁶.
- Primary Finding:
- Vaginal delivery rate:
- Induction: 38%
- Expectant Management: 31.8%
- Adjusted odds ratio = 1.32 (CI: 1.28–1.36) in favor of induction.
- Vaginal delivery rate:
- Maternal Morbidity:
- Operative vaginal delivery higher in the induction group.
- Major outcomes (uterine rupture, hysterectomy, ICU, transfusion) rare and not significantly different between groups (0.9% in both).
- Interpretation:
- Contradiction to Prior Guidance: Induction here is associated with higher—not lower—VBAC success, without an uptick in major complications.
- Patient Autonomy Emphasized: Both approaches are reasonable; patient choice remains central.
Notable Quote:
- “Patients induced at 39 weeks were more likely to have a vaginal delivery when compared to those expectantly managed. It was 38% versus 31.8%.” — [15:45]
- “Among those who had a vaginal delivery, induction of labor was associated with increased likelihood of operative vaginal delivery, and the maternal morbidity composite occurred in 0.9% in both the induction and the expectant management group.” — [17:00]
5. Closing Reflections & Clinical Pearls
- Limitations Discussed:
- Database limitations (birth certificate data—not full medical records).
- Results may mask important clinical variables (e.g., Bishop score at induction, indication for primary cesarean).
- Medicine: Both Art and Science:
- Conflicting data is the norm; share decision-making is key.
- Dr. Chapa underscores the importance of supporting patient choice and ongoing learning.
- Final Clinical Takeaway:
- Counsel patients that both induction at 39 weeks and expectant management are reasonable for TOLAC—a true “he said, she said” scenario.
- Latest evidence suggests induction may be more favorable than previously thought in this low-risk TOLAC group.
Notable Quote:
- “Whatever the patient chooses seems to be the right one. So our job should be to be supportive, educational, and say, ‘You really do have two options here, and it's a he said, she said about which is the right way to go.’ ” — [19:45]
Important Timestamps
- [00:57] – Episode premise: New data at odds with past guidance
- [05:00–08:00] – Review of ACOG’s 2019 TOLAC/VBAC induction guidance
- [11:00–13:30] – New study setup and inclusion/exclusion explained
- [14:58] – Results breakdown: rates, odds ratios, key findings
- [17:00] – Morbidity outcomes detailed
- [18:30–20:30] – Clinical context, limitations, and summary
Memorable Moments & Quotes
“Medicine... shouldn’t get you frustrated. Actually should get you pretty fired up—that it really is a science on the one hand and an art on the other.” — Co-host, [04:55]
“Direct contrast to what we just read from 2019... patients who had induction were more likely to have a vaginal delivery compared with expected management.” — [15:52]
“That’s why we keep learning. That’s why medicine is lifelong learning. Because just when you think you figured it out—chances are, you probably haven’t.” — [21:10]
Summary Table: TOLAC in Low-Risk Women, Single Prior C-Section
| Approach | ACOG 2019 Guidance | New 2025 Data | |------------------------|----------------------|---------------------------------| | Induction | Lower VBAC success | Higher VBAC success (38%) | | Expectant Management | Higher VBAC success | Lower VBAC success (31.8%) | | Uterine Rupture | Slight increase | No significant difference | | Maternal Morbidity | Not specified | No significant difference |
Final Clinical Pearl
There is now strong, new data showing induction at 39 weeks for low-risk TOLAC candidates may actually increase the chance of vaginal delivery, without added morbidity, compared to waiting for spontaneous labor—contradicting long-held beliefs. Practice shared decision-making and stay tuned for further updates as the evidence evolves!